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proposing a deﬁnition of structural progression and a deﬁnition of
unacceptable symptom state.
Methods: The group in charge of the “unacceptable symptom
state” ﬁrst decided to focus on 2 domains e.g. pain and functional
impairment, second to propose new tools for evaluating such
domains, and third to conduct a cross sectional study in order to
propose a threshold of the value in such tools above which the
level of symptoms will be considered as not acceptable. For such
purpose, the opinion of the orthopedists concerning their visiting
patients (e.g. good candidate for total articular replacement yes/no)
was considered as the gold standard.
Results: An OARSI-OMERACT pain tool and an OARSI-
OMERACT function hip/knee tools have been elaborated [1–3].
The study aimed at proposing a threshold in such tools for deﬁn-
ing a non acceptable symptom state has recruited more than 2000
patients in more than 10 different countries.
Conclusions: Such joint OARSI-OMERACT initiative should facil-
itate the conduct of clinical trials to more accurately evaluate not
only symptomatic but also disease modifying treatments.
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ADVANCES IN THE UNDERSTANDING OF THE ROLE OF
AGING IN THE DEVELOPMENT AND PROGRESSION OF OA
J. Haag
Inst. fuer Pathologie, Leipzig, Germany
The prevalence of primary osteoarthritis (OA) increases with age.
Aging, therefore, represents a major risk factor for OA. Cartilage
degradation is most certainly not simply an effect of wear and
tear processes but is signiﬁcantly inﬂuenced by molecular reg-
ulatory systems. However, the degree to which regulated aging
processes are responsible for the loss of tissue function in OA is
not yet fully resolved. Several experimental ﬁndings are consistent
with a senescent-like state of arthritic chondrocytes and cartilage.
These include a shortening of the telomere ends, the expression
of senescence markers like SA-βgal, altered cytokine expression
proﬁles and age-dependent modiﬁcations of the extracellular ma-
trix. Our own results show an increased transcriptional noise and
elevated DNA damage levels in OA chondrocytes.
The process of aging is not an unregulated process but is
regulated by evolutionary conserved pathways that safeguard
the maintenance of cellular homeostasis. The deregulation of
these regulatory networks is linked to the development of aging-
associated diseases. In this respect, perturbations of the so-
matotrophic axis (GH-IGF-Akt) are of special interest. Mice with
reduced IGF-1 and insulin signaling (Ames and Snell dwarf mice,
Klotho-overexpressing mice) live signiﬁcantly longer than littermate
mice and show an overall reduction of aging-related pathological
changes. Interestingly, long-lived Snell dwarfs (which do not pro-
duce growth hormone) show a delay of articular cartilage aging
and do not develop OA at an age when up to 58% of their wild-type
littermates already do.
Our own research provides evidence for a major perturbation of
the IGF-Akt-FoxO signaling pathway in human osteoarthritic knee
cartilage with reduced FoxO expression levels and an overall
reduction of the expression of important stress-response genes
concomitant with higher cellular damage levels. The transcript
levels of all four known FoxO genes, FoxO1, FoxO3a, FoxO4
and FoxO6 were signiﬁcantly reduced in the osteoarthritic tissue.
This decrease was more pronounced in late osteoarthritic carti-
lage compared with early degenerated tissues. Several important
FoxO target genes were substantially deregulated. The cell cycle
regulators p21, p27 and cyclin G2 were signiﬁcantly downregu-
lated, while cyclin D1 was markedly upregulated, corresponding
to the downregulation of FoxO levels. The FoxO regulated genes
involved in oxidative defense also showed differential regulation.
The expression of SOD genes was substantially reduced in OA,
with SOD2 showing the most substantial decline. mRNA levels of
GADD45, a gene involved in DNA repair, were markedly lower in
osteoarthritic tissue.
The emerging insights into the mechanisms underying general ag-
ing processes promise to open up new avenues for drug discovery.
The identiﬁcation of pharmacologically tractable drug targets within
these conserved aging pathways will make it possible to develop
novel therapeutic options for age-related diseases, including pri-
mary osteoarthritis. We expect, therefore, that further insights on
the role of natural aging processes in the development and pro-
gression of primary osteoarthritis, and thus a better understanding
of the processes underlying cartilage aging and degradation, will
translate into novel ideas and ways of preventing and treating OA.
I-6
BASIC PERSPECTIVE ON THE ROLE OF BIOMARKERS IN
THE DIAGNOSIS AND MONITORING OF OSTEOARTHRITIS
D. Heinegård
Lund Univ., Lund, Sweden
An opportunity to detect early stages of process leading to clinical
osteoarthritis (OA) is offered by the emerging molecular marker
technology. This development will be further advanced when mark-
ers with spatial, temporal and process speciﬁcity become available.
Molecular markers have the potential to provide information the
relative activity of the process of degradation and repair attempts,
including an inadequate tuning of the synthesis of new constituents
of the matrix.
markers with apparent tissue speciﬁcity: There are a number of
molecules that are released from cartilage as a result of the local
process. These include aggrecan, where the fragments containing
the chondroitin sulfate chains appear early in disease and are
formed also in the normal tissue turnover. The ﬁne structure of
the glycosaminoglycan side chains change both with age and in
disease.
The G1 hyaluronan binding domain is initially retained in the tissue
bound to hyaluronan to be released in late stage tissue injury.
Cleavage of Aggrecan at several speciﬁc sites by ADAMTS-family
members provides unique cleavage sites and neo-epitope anti-
bodies only recognizing fragments with an end corresponding the
cleavage are available and applied to studies of joint disease.
Collagen type II epitopes studied include those of the telopeptides
at the ends of the molecule and those from cleavages of the
triple helical region. Applications of these assays demonstrate
increased release of fragmented collagen in osteoarthritis. There
are discussions on the speciﬁcity of some of these assays.
New synthesis of collagen can be detected by the production and
release of the propeptides cleaved of the precursor procollagen II.
Such assays have been employed in studies of collagen synthesis
in joint disease.
Spatial speciﬁcity is possible to obtain by using proteins which are
present in only a given tissue compartment.
Interterritorial distribution: Examples of such proteins are CILP
and COMP. Both occur preferentially in the interterritorial matrix
of the adult articular cartilage.
COMP is released at an early stage of joint disease. Accordingly
elevated COMP levels may serve as a predictor of destruction of
the cartilage identiﬁed by imaging years later. One shortcoming
of many of currently employed assays, including for COMP, is
the background provided by turnover in normal cartilages. As a
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consequence, clearly elevated levels in the circulation is seen only
in individuals with the most active disease. New assays that depict
cleavage neoepitopes of ECM-molecules, show a much more
clear distinction between healthy individuals from such affected by
osteoarthritis.
Territorial distribution: Collagen VI and biglycan are particularly
present in the territorial matrix close to the cells. At this time there
are no assays available for these proteins and they may show too
wide a tissue distribution for use as speciﬁc indicators of a process
in the cartilage. Temporal speciﬁcity is a result of the breakdown of
different proteins at different stages of the OA-process in the carti-
lage, e.g. demonstrated by stimulating cartilage breakdown using
cytokines relevant to the disease process. Available data show
that aggrecan is released in early phases, leaving the hyaluronan
binding part of the molecule in the tissue. COMP and ﬁbromodulin
are release at a later stage and the preferential cleavage of the
major collagen II and its release follows in a ﬁnal phase.
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THERAPEUTIC APPLICATIONS OF MESENCHYMAL
STROMAL CELLS IN OSTEOARTICULAR DISEAES
C. Jorgensen
Hôpital Lapeyronie, Montpellier, France
Purpose: Multipotent mesenchymal stromal cells (MSC) are adult
stem cells characterized by their differentiation potential into mul-
tiple lineages and their immunosuppressive properties. This last
property is used here to evaluate the efﬁcacy of primary MSC
to inhibit inﬂammation-associated symptoms in the murine exper-
imental model of collagen-induced arthritis (CIA). Mesenchymal
stem cells (MSC) are considered suitable sources for cell-based
therapies in cartilage engineering. However, their potential to re-
generate a fully functional and mature tissue relies on the presence
of a differentiation factor. The identiﬁcation of such a factor spe-
ciﬁc for the chondrogenic lineage has still to be performed and
represents the major issue of this study.
Bone marrow-derived human MSC were induced to differenti-
ate towards chondrocytes using the micropellet culture technique
in presence of chondrogenic medium containing hBMP-2 for 21
days. Total RNA were hybridized on DNA microarrays (Affymetrix
U133A). Among the 1354 differentially regulated genes during
chondrogenesis, 705 genes were up-regulated in MSC-derived
chondrocytes. We ﬁrst focused our attention on transcription fac-
tors and in particular, on Foxo1A which was shown to be increased
by a 13-fold factor using real time PCR, as soon as day 2 of chon-
drogenesis. After the over-expression of the wtFoxo1A or mutated
Foxo1A genes in the C3H10T1/2 cells, we could show the up-
regulation of aggrecan, collagen IIB and the down-regulation of
collagen I, suggesting that Foxo1A is sufﬁcient to induce chondro-
genesis.
To demonstrate the immunosuppressive effect of MSC, we injected
the cells IV in arthritis. MSC were isolated from DBA1 mice and
wild type (wt), inducible nitric oxid synthase (iNOS)-/- or IL-6-/-
C57Bl6 mice. 106 MSC were intraveinously injected at various
times after collagen II immunization of DBA1 mice. Arthritis was
evaluated by the measure of paw swelling. In the CIA model, when
injected on day 18 and 24, syngeneic and allogeneic MSC were
able to signiﬁcantly decrease the incidence and clinical signs of
arthritis. Compared to wt MSC, iNOS-/- or IL-6-/- exhibited a highly
reduced immunosuppressive effect. When iNOS-/- or IL-6-/- MSC
were injected the clinical scores and incidence were signiﬁcantly
increased.
Conclusion. Foxo1A is one essential transcription factor involved
in the early steps of chondrogenesis. Moreover, allogeneic MSC
injection have anti-iﬂammatory effects through iNOS and that could
be relevant for osteoarthritis therapy.
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COPING WITH THE PAIN OF OSTEOARTHRITIS: UPDATE
AND NEW DIRECTIONS
F. Keefe
Duke Univ. Med. Ctr., Durham, NC
Purpose: There is growing recognition that the way that persons
cope with the pain of osteoarthritis not only inﬂuences their pain,
but also their psychological distress and physical disability. This
presentation provides an update on recent research in this area.
The presentation is divided into three sections. In the ﬁrst section,
a conceptual background for research on pain coping is presented.
The second section highlights recent research on key topics in the
arthritis pain coping literature include studies of active coping,
pain catastrophizing, biological mechanisms, and the effects of
pain coping skills training protocols. The ﬁnal section highlights
important new directions for research in this area including stud-
ies of partner-assisted coping interventions and the impact of
maladaptive pain coping behaviors (e.g. overeating, smoking).
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ANIMAL HISTOPATHOLOGY - DOG
K. Kuroki, J.L. Cook
Comparative Orthopaedic Lab., Univ. of Missouri, Columbia, MO
Purpose: Osteoarthritis (OA) is a common orthopaedic disease
seen in clinical canine patients and as such the dog is an often-
used model for study of OA. Histologic assessment of OA is
currently considered the “gold standard” for determining presence,
extent, and severity of disease. The vast majority of experimen-
tal and clinical canine OA studies have used the Mankin system
(Mankin et al. J Bone Joint Surg 1971;53A:523-37) or modiﬁ-
cations of this system to histologically evaluate OA. While this
methodology has produced useful data, limitations have been
suggested including: 1) lack of assessment of the joint as a whole,
2) inadequate representation of the relative importance of various
types of pathology, and 3) lack of a standardized methodology. The
purpose of our work was to ﬁrst develop and validate a histologic
assessment system to address these shortcomings, and then use
the novel system to examine stiﬂe joints in a prospective study
comparing three different canine models of OA.
Methods: The OARSI Histopathology Initiative Assessment Sys-
tem in the Dog was developed with a team of experts and analyzed
for reliability. For use of the system in the prospective study, sixteen
dogs received one of three different arthroscopic insults including
anterior cruciate ligament transection (n=5), full-thickness grooves
created on the medial femoral condyle (n=6), or release of the
caudal horn of the medial meniscus (n=5), to provoke OA in the
right stiﬂe (knee) joints. Dogs that received a sham surgery (n=5)
served as controls. Twelve weeks after surgery the dogs were
euthanatized and the operated stiﬂe joints and non-operated con-
tralateral stiﬂe joints were histologically evaluated using the OARSI
system and the Mankin system.
Results: The OARSI system was shown to be reliable for pro-
ducing consistent and repeatable scores and grades for cartilage,
osteochondral, and synovial tissue status. The data also suggest
that non-experienced observers using the system for the ﬁrst time
can effectively assess tissues to acceptable levels of agreement
with experts. In the prospective study, both the OARSI system and
Mankin system were judged acceptable for determining presence
and severity of OA. Statistically signiﬁcant differences among OA
severity categories were more often observed using the OARSI
system.
Conclusions: It is important to consider OA as a “whole organ
disease” and keep in mind that a tissue section does not always
